Functional TRIM24 degrader via conjugation of ineffectual bromodomain and VHL ligands
Lara Gechijian(Jnana Therapeutics (United States)), James E. Bradner(Novartis (China)), Jennifer A. Perry(Dana-Farber Cancer Institute), Joshiawa Paulk(Novartis (United States)), Nathanael S. Gray(Stanford University), Matthew A. Lawlor(Dana-Farber Cancer Institute), Jaime M. Reyes(Dana-Farber Cancer Institute), Georg E. Winter(CeMM Research Center for Molecular Medicine), Michael A. Erb(Scripps Research Institute), Hyuk‐Soo Seo(Dana-Farber Cancer Institute), Jun Qi(Georgia Institute of Technology), Mousheng Xu(Dana-Farber Cancer Institute), Dennis L. Buckley(Novartis (United States)), Nicholas Kwiatkowski(Woomera Therapeutics), Christopher J. Ott(Broad Institute), Sirano Dhe‐Paganon(University of Toronto), Thomas G. Scott(Dana-Farber Cancer Institute)
Cited by 229
Related Papers
A Landscape of Pharmacogenomic Interactions in Cancer
|Cell|2016|2.3k
An ATP-competitive Mammalian Target of Rapamycin Inhibitor Reveals Rapamycin-resistant Functions of mTORC1
|Journal of Biological Chemistry|2009|1.8k
Crystal Structure of the Tyrosine Phosphatase SHP-2
|Cell|1998|1k